About us

CSR

Corporate Social Responsibility

Ability Pharmaceuticals is an innovative and responsible company regarding the relationship with our stakeholders, suppliers, partners, institutions, employees, the environment and society. The objective of our Corporate Social Responsibility is to achieve a sustainable development of the company, understood as a balanced growth in the economic, social and environmental dimensions. At Ability Pharmaceuticals we integrate all of our stakeholders with the commitment to develop cancer medications to improve clinical outcomes through improved efficacy and increased safety.
 
Knowledge sharing and co-development are highly valued at Ability Pharmaceuticals. We work with an extensive network of excellent external partners, from the public and private sectors, with the aim of creating new projects and generating new business opportunities. Ability Pharmaceuticals breaks traditional boundaries between partner companies and promotes the integration of resources and ideas among development groups, organizations and different business units.
 
Ability Pharmaceuticals promotes ethical behavior that builds trust and brings value. That is why the company maintains a responsible, fluid and bidirectional communication with the main interest groups, about the policies, practices and results of our projects. In addition, Ability Pharmaceuticals is committed to respect the ethical codes, carrying out all our activities with professional, ethical and total transparency.
 
We believe that our employees are critical to our social commitment and we are aware that attracting, training and working with tomorrow's leaders and innovators is vital to helping us achieve our business philosophy. That is why Ability Pharmaceuticals supports the training and professional development of all its employees, facilitating family reconciliation and work, as part of the retention strategy of the extraordinary professionals who form the company. Moreover, the company is committed to equal opportunity for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, language or disability.
 
We have a great commitment to the environment, considering fundamental the protection of the field in which our business is developed, since only this way can maintain a sustainable and lasting activity. We promote a healthy and safe work atmosphere for our employees, continually improving to protect the health, safety and welfare of workers.

LATEST NEWS

11.03.2024

Press Release

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023

Press Release

Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022

Press Release

AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022

Press Release

AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022

Press Release

AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
02.11.2022

Press Release

ABTL0812 shows potential against glioblastoma brain tumors + info
07.10.2022

Press Release

AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812 + info
07.09.2022

Press Release

Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer + info
29.06.2022

Press Release

AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG